

Prescribing Information

Liothyronine sodium 20 micrograms tablets

Presentation: Each tablet contains 20mcg Liothyronine sodium BP.

Indication: For treatment of coma of myxedema, the management of severe chronic thyroid deficiency and hypothyroid states because of its rapid and more potent effect.

Dosage and Administration: For oral administration.

Adults: Starting dose of 10 or 20 micrograms every 8 hours or increasing to the usual recommended daily dose is 60mcg in two or three divided doses. **Elderly and Children:** 5 micrograms daily (Tertroxin tablets can be crushed and triturated with lactose).

Contraindications: Patients with angina of effort, cardiovascular diseases, thyrotoxicosis or hypersensitivity to any components of the tablet.

Precautions and Warnings: Caution in patients with severe and prolonged hypothyroidism, diabetes mellitus, diabetes insipidus and patients with myxedema by avoiding excessive imposition of burden on cardiac muscle affected by prolonged severe thyroid depletion. Pan hypopituitarism or predisposition to adrenal insufficiency. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medication.

Interactions: A number of drugs like anticoagulants, cardiac glycosides, Colestyramine, colestipol, antidiabetic agents, catecholamine's, oral contraceptives, Anticonvulsants like carbamazepine and Phenytoin, Amiodarone, Amitriptyline and oestrogens may affect thyroid function tests and this should be borne in mind when monitoring patients on Liothyronine therapy.

Pregnancy and Lactation: Safety of the drug during pregnancy

is not known. The risk of foetal congenital abnormalities should be weighed against the risk to the foetus of untreated maternal hypothyroidism. Tertroxin is excreted into breast milk in low concentrations which may interfere with neonatal screening programmes.

Undesirable effects: Anginal pain, cardiac arrhythmias, palpitations, muscle cramps, tachycardia, diarrhoea, restlessness, excitability, headache, flushing, sweating, excessive loss of weight and muscular weakness, vomiting, tremor, insomnia, fever, heat intolerance, transient hair loss in children, hypersensitivity reactions including rash, pruritus and oedema may occur and will disappear on reduction of dosage or withdrawal of treatment for a day or two.

Please refer Summary of Product Characteristics for detailed information

Overdose: Signs and symptoms may include agitation, confusion, irritability, hyperactivity, headache, sweating, mydriasis, tachycardia, arrhythmias, tachypnoea, pyrexia, increased bowel movements and convulsions.

Treatment of overdose is symptomatic but gastric lavage or emesis can be performed if patient is seen within a few hours of overdose.

Legal Category: POM

Basic NHS Cost: £52.46 per pack of 28 tablets

Marketing Authorization Number: PL 10972/0033

Marketing Authorization Holder: Amdipharm Mercury Company Limited, NLA Tower, Croydon, CRO OXT.

Date of preparation: 23 August 2012

Date of revision: June 2013

Adverse events should be reported to the local regulatory authority.

Reporting forms and information can be found at <http://www.mhra.gov.uk/yellowcard>

Adverse events should also be reported to **Amdipharm Mercury Medical Information** on **+44(0)8700 70 30 33**

or by email to **medicalinformation@amcolimited.com**